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Background: The ATP-Binding Cassette (ABC)-transporter MultiDrug Resistance Protein 1 (MDR1) and Multidrug
Resistance Related Protein 1 (MRP1) are expressed on the surface of enterocytes, which has led to the belief that
these high capacity transporters are responsible for modulating chemosensitvity of colorectal cancer. Several
immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) studies have provided
controversial results in regards to the expression levels of these two ABC-transporters in colorectal cancer. Our study
was designed to determine the yet uninvestigated functional activity of MDR1 and MRP1 transporters in normal
human enterocytes compared to colorectal cancer cells from surgical biopsies.
Methods: 100 colorectal cancer and 28 adjacent healthy mucosa samples were obtained by intraoperative surgical
sampling. Activity of MDR1 and MRP1 of viable epithelial and cancer cells were determined separately with the
modified calcein-assay for multidrug resistance activity and sufficient data of 73 cancer and 11 healthy mucosa
was analyzed statistically.
Results: Significantly decreased mean MDR1 activity was found in primary colorectal cancer samples compared to
normal mucosa, while mean MRP1 activity showed no significant change. Functional activity was not affected by
gender, age, stage or grade and localization of the tumor.
Conclusion: We found lower MDR activity in cancer cells versus adjacent, apparently, healthy control tissue, thus,
contrary to general belief, MDR activity seems not to play a major role in primary drug resistance, but might rather
explain preferential/selective activity of Irinotecan and/or Oxaliplatin. Still, this picture might be more complex since
chemotherapy by itself might alter MDR activity, and furthermore, today limited data is available about MDR activity
of cancer stem cells in colorectal cancers.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1675739129145824Background
ABC-(ATP-Binding Cassette) transporters are trans-
membrane proteins expressed in the physiological bar-
riers of the human body pumping out a high diversity of
substrates (toxins, chemotherapeutics, medications, bile
acids etc) from the cells and thus have important role in
the detoxification of our body against xenobiotics. Acti-
vation of the same MDR-transporters of cancer cells can* Correspondence: micsikt@gmail.com
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response to chemotherapy [1].
The clinically most important ABC-transporters are the
MDR1 (MultiDrug Resistance protein 1, P-glycoprotein-
170) having prognostic role in acute myeloid leukemia [2],
sarcomas [3,4] and gallbladder carcinoma [5]; and MRP1
(Multidrug resistant Associated/Related Protein 1), which
has prognostic relevance in neuroblastoma [6], hepatocel-
lular carcinoma [7] and in non small cell lung cancer [8].
Based on the high expression of the ABC-transporters
along the gastrointestinal tract [9] and the intrinsic low re-
sponse rate of GI cancers to chemotherapy, colorectal can-
cer was thought to be chemoresistant due to MDR-proteinsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Basic clinicopathological characteristics of
studied primary ColoRectal Cancer cases included in
statistical analysis
CRC = 73 Average age Mucosa = 11
Males 39 65,2 7
Females 34 68,6 4
Right colon:20 Coecum:12 Ascendens:8
Left colon:53 Descendens:7 Sigma:17 Rectum:29
Grade Grade I:9 Grade II:53 Grade III:11
T1:5 T2:20 T3:36 T4:12
TNM Stage I:22 TNM Stage II:21 TNM Stage III:11 TNM Stage IV:19
T1N0M0:4 T1N0M1:1 T2N0M0:18 T2N1M0:2
T3N0M0:18 T3N0M1:3 T3N1M0:9 T3N1M1:6
T4N0M0:3 T4N1M1:9
pTNM version 6 was used during data collection. (CRC: Colorectal Cancer; pTNM:
pathological TNM-stratifictaion).
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[14-19]. The main therapy of colorectal cancer is the sur-
gical resection of the tumor in combination with chemo
(radio) therapy. Chemotherapeutic regimens were initially
based on 5-fluorouracil (5FU - neither MDR1 nor MRP1
substrate), but recently Irinotecan (MDR1 substrate) and
Oxaliplatin (MRP1 substrate) were also introduced in
combination with monoclonal antibodies and resulted in
better response-rate and survival rate even in metastatic
cases [20,21].
As newer chemotherapeutics raised the possible role
of MDR-transporters’ activity in response to therapy, we
decided to study the functional activity of MDR1 and
MRP1-proteins in freshly isolated viable colon carcin-
oma cells and normal epithelial cells with the modified
calcein assay [22]. In our study of 73 cancer and 11 nor-
mal mucosa we found that MDR1 functional activity of
colorectal cancer cells was decreased compared to nor-




Clinical samples were obtained after approval by the na-
tional and local Ethical Committees at the Department
of Surgery and Vascular Surgery of the Uzsoki Teaching
Hospital, Budapest. All patients were enrolled after
written consent and altogether 100 samples of primary
colorectal cancer and 28 normal mucosal samples were
taken into RPMI 1640 (11875-093, Gibco Invitrogen,
Grand Island, NY) medium within 30 minutes after
devascularization. Colon cases (n = 44) were chemother-
apy naïve, while rectal cases (n = 29) received previous
chemo-radiotherapy. The samples were stored at 4°C
until being processed. Clinicopathological characteristics
of the cases involved in the statistical analysis are shown
in Table 1.
Modified Calcein assay for solid tumors
The samples were processed with the modified calcein
assay [22]. Surgical samples were cut into small pieces,
washed in HBSS buffer (14025-092, GIBCO Invitrogen,
Csertex, Budapest, Hungary) then incubated in 1 ml of
4 mg/ml collagenase (LS004212, Worthington collagenase
type IV, Worthington Biochemical Corporation, NJ) while
continuously mixing for 10 min at 37°C. The reaction
was stopped by adding 200 μl 10% FBS (Foetal Bovine
Serum – F-2442, Sigma-Aldrich, Budapest, Hungary).
After filtering and washing the samples in HBSS, 600
μls of the yielded single-cell suspension were aliquoted
into seven tubes.
The dual MDR1 and MRP1 inhibitor Verapamil (V4629,
Sigma-Aldrich, Budapest, Hungary) was diluted in HBSS
to 250 μM and 200 μl was added to three vials. The MRP1inhibitor MK571 (340-021-M005, Alexis Biochemicals,
Bio-Marker, Gödöllö, Hungary) was diluted in HBSS to
50 μM and 200 μl was added to another two vials. 200 μl
HBSS buffer was added to the remaining two control vials.
All samples were mixed gently, but thoroughly and subse-
quently 200 μl of 50 nM HBSS-diluted calcein-AM (C3100,
Molecular Probes, Bio-Science, Budapest, Hungary) was
added to each sample and incubated for exactly 10 minutes
at 37°C. Samples were then rapidly chilled on ice for 5 mi-
nutes and spun down. Supernatant was discarded and
cells were resuspended in 200 μl HBSS containing 2 μg/
ml 7-AAD (AminoActiomycinD – A9400, Sigma-Aldrich,
Budapest, Hungary). 1 μg of isotype negative control
mouse IgG1 (X093101-2, Dako-Frank Diagnosztika Kft.,
Budapest, Hungary) was added to one Verapamil treated
sample and 1 μg of anti-BerEP4 mouse IgG1 antibody
(M080401-2, Dako, Budapest, Hungary) to the other six
samples. Subsequently, 0,5 μg of secondary Cy5 conju-
gated goat anti-mouse IgG antibody (115-175-003, Jack-
son Immuno Research, Izinta, Budapest, Hungary) was
added to each sample and incubated in dark at room
temperature for 30 minutes. Samples were spun down and
resuspended in 200 μl HBSS containing 1 μg/ml 7-AAD
and kept on ice until measurement.
Flow cytometric analysis was performed on Becton
Dickinson FACSCalibur flow cytometer as shown in
Figures 1, 2 and 3. Calcein signal was detected on FL-2
instead of the usual FL-1 for better electronic compensa-
tion (for details see [22]). Viable cells were gated and
selected based on the positive calcein (FL-2) and negative
7-AAD (FL-3) signal of those and further analyzed on the
FL4 (BerEp4 signal) and SSC diagram (Figure 1). BerEP4
negative cells were excluded with parallel gating of IgG
negative control and BerEp4 samples (Figure 2) and
calcein signal shifts of BerEp4 and calcein positive, but
Figure 1 Description of the gating procedure of the viable epithelial cells. FSC-SSC dot-plot was used for the visualisation of the various cell
populations in this sample of a colorectal cancer. The viable cells (which were negative for 7AAD and positive for calcein) were selected with R1
gate on FL2 (calcein fluorescence)-FL3 (7AAD signal) dot-plot. R1 was further analyzed for gating out viable epithelial cells with R2 on two parallel
FL4-SSC dot-plots of isotype control (middle, left) and BerEP4 antibody binding (middle, right) upon high FL4-BerEP4-positivity. Lower tables show
number of cells in each gate. Only cells within R1 and R2 gates were used for the determination of the functional activity of MDR1 and MRP1 transporters.
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ples (Figure 3).
Our assay used the Calcein-AM as a known substrate
for both examined transporters. With the two trans-
porter inhibitors (Verapamil for both MDR1 and MRP1
and MK571 only for the MRP1) the assay calculates the
individual functional activity of both transporters as MAF-
values (Multidrug Activity Factor) of the given sample.
MAF values were calculated from the means of calcein
fluorescence signals detected with the control HBSS and
with the two inhibitors according to the mathematic
formula: MAFTotal = 100 × (FVerapamil − FHBSS)/FVerapamil;
MAFMRP1 = 100 × (FMK571 − FHBSS)/FVerapamil; MAFMDR1 =
MAFTotal – MAFMRP1, where F denotes the mean Calcein-
fluorescence value determined as the average of the two
parallel FL2 signals in the different samples. Samples with
highly active MDR1 and MRP1 functional activity giveMAF around 20-40, or higher, while samples without sig-
nificant activity would show values of 0-5. Negative values
are probable signs of other active transporters than MDR1
or MRP1.
The absolute number of all cells and viable cells, and
the absolute number and percentage of viable epithelial
cells were determined in each sample. The MAF-values
were not affected by the cell number or cell viability or
elapsed time from surgical sampling. Experiments yielding
too few viable epithelial cells (under 100) were excluded,
thus altogether 11 normal and 73 tumor samples could
have been included in the statistical analysis.
Results were tested for normal distribution using the
Kolmogorov-Smirnov test with Lilliefors significance cor-
rection. Homogeneity of variances was evaluated using
the Levene test. For analysis of the variables that slightly
derived from normal distribution and homoscedasticity,
Figure 2 Determining the percentage of viable epithelial cells. The
percentage of epithelial cells among viable cells was calculated on
FL4 histograms with M1 upon their positivity with BerEp4 (upper graph)
compared to isotype control (lower graph). Here 90,50% - 4,82% =
85,68% of viable cells proved to be BerEP4 positive viable epithelial
cells. Graphs are representing similar data as the two middle graphs in
Figure 1, but numerical analysis worked better with this representation.
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[23], while other parameters were compared by equal vari-
ance t-test. Data are presented as mean +/- SD if normal,
and median and inter-quartile range if non-normal. Data
analysis was performed using the SPSS 17.0 software
(SPSS Inc., Chicago, USA).
Results
There was a significant decrease (p = 0.03) in the MAFTotal
values of colorectal cancer cases (MAF: -7.80 ± 14.43)
compared to the adjacent, apparently normal mucosa
(MAF: 2.08 ± 11.17). This decrease was mainly due to theFigure 3 Calculating the MAF-values of viable epithelial cells. The function
(calcein fluorescence) histograms showing the impact of the various MDR
(Verapamil blocks MDR1 and MRP1) histogram and the MRP1 inhibitor (MK
middle). In this sample no shift could have been seen with either inhibitor
was the following: MAFTotal = 100 × (FVerapamil – FHBSS)/FVerapamil; MAFMRP1 =
F means the mean Calcein-fluorescence values determined on FL2 in the d
FHBSS (Control) = 730, FMK571 (MRP1 inhibitor) = 737; which equals MAFTotal = 1, MAsignificant (p = 0.05) decrease in MAFMDR1 of colorectal
cancer cases (MAF:-3,9 ± 12,12) compared to normal
mucosa (MAF: 3,13 ± 10,30), while MAFMRP1 values did
not differ significantly (p = 0.4), -3.9 ± 14,23 in cancer
versus -1,05 ± 9,69 in normal mucosa (Figure 4). The
highest MAF-values were detected among the healthy
samples and the lowest MAF-values among the cancer
samples.
The percentage of epithelial cells and viable cells, and
also the heterogeneity and absolute calcein fluorescence
values of cells were not significantly different between
the control and tumor groups, meaning that the two
groups were not different in their main characteristics.
ANOVA analysis of tumor localization, left or right sided
tumors, TNM stage, grade, age and gender or previous
chemo-radiotherapy showed minor, not significant dif-
ferences in MAF values of MDR1 and/or MRP1.
Discussion
Because of their high expression in normal gastrointes-
tinal epithelium, MDR1 and MRP1 proteins were con-
sidered to be also highly active in colorectal cancers
[12]. Early investigations showed higher mRNA and ex-
pression levels of MDR1 in colorectal cancers [24], and
carcinogenesis [10,11,13], but immunocytochemical [14]
and immunoblotting studies [15] have found decreased
MDR1 expression in tumor cells compared to the main-
tained expression in normal mucosa. Furthermore, dis-
crepancy was described between MDR1 mRNA levels
and MDR-phenomenon, concluding that phosphorylation
status and localisation of MDR1 showed the strongest
correlation with functionality [16]. Some studies raised theal activity of MDR1 and MRP1 transporters are calculated with FL2
inhibitors on the mean fluorescence intensity shift. The total inhibitor
-571) histogram are compared to the control histogram (HBSS, in the
indicating low MDR1 and MRP1 functional activity. Mathematic formula
100 × (FMK571 – FHBSS)/FVerapamil; MAFMDR1 = MAFTotal – MAFMRP1. Where
ifferent samples individually. Here FVerapamil (Total MDR Inhibitor) = 736,
FMRP1 = 1, MAFMDR1 = 0
Figure 4 Categorized Box & Whisker plots showing the mean MAF-values and their standard errors in the different groups. CRC stands for the
colorectal cancer samples, while healthy mucosa means the normal adjacent mucosa taken from the resection ends. There is a significant decrease in
MAFTotal and MAFMDR1 values, while MAFMRP1 remained practically unchanged.
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studies found no impact of MDR-expression on survival
[13,27,28], not even the largest study with 102 cases [29].
More studies found decreased MRP1 expression with
no impact on survival in gastrointestinal tract carcin-
omas [30,31]. Significant association of elevated MRP2-
expression (and not MDR1 or MRP1!) was found in cis-
platin resistance [32]. Constitutive MRP1 expression was
described in a study of primary and metastatic colorectal
cancers, whereas the same study found elevated MRP1
expression in metastatic cases which underwent che-
motherapy [33], underlining the impact of previous
chemotherapy on the presence and function of these
transporters in cancer cells.
The discrepancy between expression study results and
clinical findings could be partly resolved with functional
studies, which measure the direct transport activity of
these pumps regardless of expression or any posttransla-
tional modifications. On the other hand, there are other
mechanisms possibly resulting in multidrug resistance
phenomenon, so MDR1 and MRP1 proteins might not
play key-role in colorectal malignancies [34-37]. Recent
research of cancer stem cells (CSCs) in CRC brought the
renaissance of the MDR-phenomenon, since the tumor
repopulating side population of the resistant CSCs are
expressing more ABC-transporters, especially ABCG2
(MXR, BCRP) [38-40].
The modified calcein assay for solid tumors is based
on the calcein assay used for prognostication of leukaemia
[2] with an added double viability and immunocytochem-
ical staining for selecting living cancer cells. This method
has never been used before to investigate large numbers
of colorectal samples and up to now very few data is
available on activity of these transporters either in healthy
or in tumorous colon mucosa [41]. We determined
the MDR1 and MRP1 functional activity of normal andcancerous enterocytes in 73 tumor and 11 normal mucosa
samples, representing the largest functional study by now.
According to our results, multidrug transporter activity of
healthy colon mucosa is mainly covered by the functional
activity of MDR1 protein, while MRP1 showed lower
activity (Figure 4.). The significant MDR1 transporter
activity in normal mucosa is in good correlation with
previous findings that normal enterocytes express func-
tioning MDR1 transporters. The significant lower mean
MAFTotal-values detected in our colorectal cancer samples
were mainly generated by the significant decrease in the
mean functional activity of MDR1 transporter, while
MAF-MRP1 was practically unchanged.
For now preoperative radio-chemotherapy represents a
routine clinical practice in rectal cancers, which means
neoadjuvant 50 Gy irradiation combined with 5-FU of
the rectal cancers. This treatment had no significant
effect on activity of MDR1 and/or MRP1 proteins in
the rectal cases (n = 29) involved in our study. Not any
other significant differences were found either between
the various location of tumors or between left and right
sided tumors.
The chemotherapy of colorectal cancer is based on 5-
FU, which is neither MDR1 nor MRP1 substrate, but now-
adays chemotherapeutic regimen is widening. Irinotecan
(MDR1 substrate) and Oxaliplatin (MRP1 substrate) drugs
were also involved and succeeded to increase the survival
rate of patients. With these newer agents the MDR1 and
MRP1 functional activity might influence the response to
therapy and possibly also the survival of patients. Func-
tional data determined with our modified calcein-assay
protocol could provide more information and insight into
the function of MDR-transporters in colorectal diseases.
As clinical follow up is in progress, we will be able to
study the impact of MDR1 and MRP1 functional activity
on the survival of patient in several years.
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In conclusion, our study is the first one to use the modi-
fied calcein-assay to determine the MDR1 and MRP1
functional activity of enterocytes and cancer cells from lar-
ger numbers of surgical samples of colorectal cancers and
healthy mucosa. We measured the MAFTotal, MAFMRP1
and MAFMDR1 values of 100 colorectal cancer and 28 nor-
mal mucosa samples of which 73 tumor and 11 normal
mucosa gave sufficient cells for reliable statistical analysis.
We found significant decrease in the MAFTotal and
MAFMDR1 values of colorectal cancer cells compared to
the adjacent, apparently normal mucosa. Normal mucosa
showed significant MDR1 functional activity, but there
was no detectable change in the low MRP1 functional ac-
tivity between the normal and tumorous mucosa. Univari-
ate and multivariate analysis of tumor localization, TNM
stage, grade, age and gender showed no significant impact
on multidrug functional activity. Our findings are in good
correlation with previous expression studies of MDR1 and
MRP1 proteins, which underlined that the expression of
MDR1 protein in colorectal cancers is not primarily ele-
vated and probably has no impact on survival of patients.
Thus, contrary to general belief MDR activity seems not
to play a major role in chemoresistance, but might rather
explain preferential/selective activity of Irinotecan and/or
Oxaliplatin in CRC. Still, this picture might be to simple,
and it is unclear whether chemotherapy by itself might
alter this, and furthermore, today a very few is known
about MDR activity in CSC. Although, the majority of
the chemoresistance of primary CRCs might not be
mediated through MDR1 or MRP1 proteins, the com-
bination of predictive molecular diagnostics and MDR
diagnostics can potentially further contribute to the
advancement of personalized treatment of colorectal
cancer patients.
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